Product Description
Candesartan is used alone or together with other medicines to treat high blood pressure (hypertension) in adults and children 1 to 16 years of age. High blood pressure adds to the workload of the heart and arteries. If it continues for a long time, the heart and arteries may not function properly. This can damage the blood vessels of the brain, heart, and kidneys, resulting in a stroke, heart failure, or kidney failure. Lowering blood pressure can reduce the risk of strokes and heart attacks. Candesartan is also used to treat heart failure in adults and cut down on the number of hospital visits for heart problems. Candesartan is an angiotensin II receptor blocker (ARB). It works by blocking the action of a substance in the body that causes the blood vessels to tighten. As a result, candesartan relaxes the blood vessels. (Sourced from: https://www.mayoclinic.org/drugs-supplements/candesartan-oral-route/side-effects/drg-20068192?p=1)
Mechanisms of Action: AT1 Antagonist, ARB Blocker
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Approved
Approved Countries: Algeria | Argentina | Australia | Austria | Bangladesh | Belgium | Bosnia | Brazil | Bulgaria | Canada | Chile | China | Colombia | Cyprus | Czech | Denmark | Dominican Republic | Ecuador | Egypt | Estonia | Finland | France | Germany | Greece | Hong Kong | Hungary | Iceland | India | Indonesia | Ireland | Israel | Italy | Japan | Jordan | Korea | Latvia | Lebanon | Lithuania | Luxembourg | Malaysia | Malta | Mexico | Morocco | Netherlands | New Zealand | Norway | Pakistan | Peru | Philippines | Poland | Portugal | Romania | Russia | Saudi Arabia | Singapore | Slovakia | Slovenia | South Africa | Spain | Sri Lanka | Sweden | Switzerland | Taiwan | Thailand | Tunisia | Turkey | Ukraine | United Arab Emirates | United Kingdom | United States | Uruguay | Venezuela | Vietnam
Approved Indications: None
Known Adverse Events: None
Company: AstraZeneca
Company Location: Europe
Company Founding Year: 1999
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: Australia, Belgium, Canada, China, Colombia, Croatia, Czech Republic, Estonia, Finland, France, Germany, Hungary, India, Ireland, Israel, Italy, Japan, Korea, Nepal, Netherlands, New Zealand, Pakistan, Portugal, Romania, Saudi Arabia, Serbia, Slovenia, Spain, Switzerland, United Kingdom, United States
Active Clinical Trial Count: 5
Recent & Upcoming Milestones
Highest Development Phases
Phase 3: COVID-19|Hypercholesterolemia|Hypertension|Influenza, Human|Pneumonia
Phase 2: Migraine Disorders|Migraine with Aura|Migraine without Aura
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
2019-003386-18 |
CandMig III | P2 |
Completed |
Migraine without Aura|Migraine Disorders|Migraine with Aura |
2024-04-12 |
2025-05-06 |
||
NCT02735707 |
REMAP-CAP | P3 |
Recruiting |
COVID-19|Influenza, Human|Pneumonia |
2026-02-01 |
2024-11-27 |
||
CTR20242546 |
CTR20242546 | P3 |
Completed |
Hypertension |
2025-11-20 |
2026-01-18 |
Patient Enrollment|Primary Completion Date|Study Completion Date|Treatments|Trial Status |
|
NCT06646354 |
HODO-2224 | P3 |
Enrolling by invitation |
Hypertension|Hypercholesterolemia |
2025-05-19 |
2% |
2025-05-23 |
Primary Endpoints |
CTR20180046 |
CTR20180046 | P1 |
Recruiting |
Hypertension |
None |
2025-04-29 |
Recent News Events
Date |
Type |
Title |
|---|---|---|
|
06/19/2025 |
News Article |
Lundbeck Advances Leadership in Migraine With New Data at the American Headache Society 67th Annual Scientific Meeting |
|
04/09/2024 |
News Article |
Lundbeck to Present Data on Migraine Impact Reduction and Sustained Response with VYEPTI® (eptinezumab-jjmr) at 76th Annual Meeting of the American Academy of Neurology |
|
09/22/2023 |
News Article |
Massive Growth Of API of Sartan Drugs Market 2023 Size Strong Revenue and Competitive Outlook |
|
09/09/2023 |
News Article |
Candesartan Cilexetil Drug Market Trends Report 2023-2030 |